Back to Journals » OncoTargets and Therapy » Volume 12

Individualized treatment for a case of recurrent ovarian ependymoma

Authors Yuan Z, Yu M, Chen Y

Received 15 July 2018

Accepted for publication 29 November 2018

Published 20 December 2018 Volume 2019:12 Pages 113—117


Checked for plagiarism Yes

Review by Single-blind

Peer reviewers approved by Dr Colin Mak

Peer reviewer comments 2

Editor who approved publication: Dr Sanjay Singh

Zhen Yuan,1 Mei Yu,1 Yu Chen2

1Department of Obstetrics and Gynecology, Peking Union Medical College Hospital, Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China; 2Department of Obstetrics and Gynecology, LuHe hospital, Capital Medical University, Beijing, China

Abstract: Ovarian anaplastic ependymoma is a rare gynecologic malignancy. Owing to its rarity, treatment is challenging. Unilateral ovarian ependymoma was found during laparoscopy in a 19-year-old woman. After cytoreductive surgery, three cycles of bleomycin, etoposide, and cisplatin were administered. Four years after chemotherapy, the patient experienced relapse. After the secondary cytoreductive surgery, no further treatment was performed. She is in good condition, ~19 months after secondary cytoreductive surgery using hormone-replacement therapy without chemotherapy. Some cases of ovarian ependymoma can be treated with surgery alone without chemotherapy and the outcome has been satisfying. Choosing treatment based on malignant ovarian germ cell tumors may be not optimal. Therefore, we suggest individualized treatment for ovarian ependymoma.

Keywords: ovarian ependymoma, contralateral ovary, chemotherapy, hormone-based treatment

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]